BALCAO · PHARMACEUTICAL PREPARATIONS · MID CAP
PureTech Health PLC PTCHF
7 fiscal years on record · USD · FY2024 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
USD 4.8M
Revenue, FY2024 · full 7-year series below
Revenue $M
Net income $M
FY2024 · Revenue 4.8 · Net income 53.5
150.0M300.0M-25.0M-50.0M
201820212024
Compound annual growth
Revenue compounded at −13.2% a year over the five years to FY2024.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
575 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2024 · Operating -2818.9% · Net 575.4%
200%400%-2000%-4000%
201820212024
ROE
FY2024 · ROE 12.2%
50%100%-10%-20%
201820212024
Three returns, three denominators.
Each USD of equity produced 12 cents of profit this year.
The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 |
| EBITDA $B | −0.1 | −0.1 | −0.2 | −0.1 | ◌ | ◌ | ◌ |
| Income tax $B | −0.0 | 0.0 | −0.1 | 0.0 | 0.0 | 0.1 | 0.0 |
| Net income $B | 0.1 | −0.1 | −0.1 | −0.1 | 0.0 | 0.4 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 |
| EPS, diluted $ | 0.21 | −0.24 | −0.18 | −0.21 | 0.02 | 1.44 | −0.16 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — |
| ROE % | 12.2 | −13.1 | −8.9 | −9.6 | 0.9 | 100.8 | −26.0 |
| Shares out B | ◌ | 0.27 | 0.28 | 0.29 | 0.29 | ◌ | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 23 reconciliationsAUDITED
Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 14 checks were skipped: the share count is not tagged before 2021.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
Data on record since2018